Experts say 85% price drop in empagliflozin expected to boost SGLT2 usage; SGLT-2 class of drugs account for 25-30% of all diabetes prescriptions ...

Researchers sourced data from the EASE-2 and -3 clinical trials to assess the effect of SGLT2i use on cardiovascular disease risk among patients with type 1 diabetes.

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

Mumbai: Global pharma major, Lupin Limited, has received approval from the United States Food and Drug Administration (U.S.

Mumbai: Global pharma major Lupin Limited has announced that it has received the Establishment Inspection Report (EIR) from ...

Associate Health Minister David Seymour and Health Minister Simeon Brown are pleased that hundreds of thousands of New ...

Not one but two new studies published today have linked GLP-1 drugs like Ozempic to a decreased risk of developing dementia. There is currently no cure for Alzheimer’s, which affects an ...

The country’s pharmaceuticals market grew by 8.4 per cent during financial year 2024-25 on the back of major therapies showing positive value growth, according to market research firm Pharmarack.

Associate Health Minister David Seymour and Health Minister Simeon Brown are pleased that hundreds of thousands of New Zealanders are set to benefit ...